...
首页> 外文期刊>Daru Journal of pharmaceutical sciences. >Synthesis and biological evaluation of novel benzyl piperazine derivatives of 5-(5-nitroaryl)-1,3,4-thiadiazoles as Anti-Helicobacter pylori agents
【24h】

Synthesis and biological evaluation of novel benzyl piperazine derivatives of 5-(5-nitroaryl)-1,3,4-thiadiazoles as Anti-Helicobacter pylori agents

机译:新型5-苄基哌嗪衍生物5-(5-硝基芳基)-1,3,4-噻二唑类化合物的合成及生物学评价

获取原文
           

摘要

Background and the purpose of the study Helicobacter pylori is recognized as the main cause of gastritis and gastroduodenal ulcers and classified as class 1 carcinogen pathogen. Different 1,3,4-thiadiazole derivatives bearing 5-nitroaryl moiety have been shown considerable anti- H. pylori activity. In attempt to find new and potent derivatives of described scaffold, a new series of 1-(substituted benzyl)-4-(5-(5-nitroaryl-2-yl)-1,3,4-thiadiazol-2-yl)piperazine derivatives were synthesized and evaluated against three metronidazole-resistant isolates of H. pylori using paper disk diffusion bioassay test. Methods The title compounds were prepared through the reaction of 1-(5-(5-nitroaryl-2-yl)-1,3,4-thiadiazol-2-yl) piperazine 5a-b and substituted benzyl chloride in DMF. The inhibitory activity of the new derivatives 6a-q against three metronidazole-resistant isolates of H. pylori was evaluated by the disc diffusion method and compared with the commercially available standard drug metronidazole. Results and discussion The results of SAR study indicated that the potency and anti- H. pylori activity profile of synthesized derivatives is mainly attributed to the substituted nitroaryl moiety at the C-5 position of 1,3,4-thiadiazole ring. Most of 1,3,4-thiadiazole derivatives bearing 5-nitrofuran moiety at C-5 position of central thiadiazole ring, demonstrated more promising anti- H. pylori than the 5-nitrothiophen counterpart. Conclusion The most potent nitrofuran derivative containing 3-methoxybenzyl piperazine pendant at the C-2 position of 1,3,4-thiadiazole ring (compound 6i) , demonstrated strong anti- H. pylori potential at studied concentrations 100-25?μg/disk (IZD?>?20?mm) against all studied metronidazole- resistant isolates of H. pylori .
机译:研究背景和目的幽门螺杆菌被认为是引起胃炎和十二指肠溃疡的主要原因,被归类为1类致癌病原体。具有5-硝基芳基部分的不同的1,3,4-噻二唑衍生物已经显示出相当大的抗幽门螺杆菌活性。为了找到所述支架的新的和有效的衍生物,新系列的1-(取代的苄基)-4-(5-(5-硝基芳基-2-基)-1,3,4-噻二唑-2-基合成了哌嗪衍生物,并使用纸盘扩散生物测定法针对三种对甲硝唑耐药的幽门螺杆菌进行了评估。方法通过1​​-(5-(5-硝基芳基-2-基)-1,3,4-噻二唑-2-基)哌嗪5a-b与取代的苄基氯在DMF中反应制备标题化合物。通过圆盘扩散法评估了新衍生物6a-q对三种耐幽门螺杆菌的幽门螺杆菌分离物的抑制活性,并与市售的标准药物甲硝唑进行了比较。结果与讨论SAR研究的结果表明,合成衍生物的效力和抗幽门螺杆菌活性谱主要归因于1,3,4-噻二唑环C-5位的取代硝基芳基部分。在中心噻二唑环的C-5位带有5-硝基呋喃部分的大多数1,3,4-噻二唑衍生物显示出比5-硝基噻吩对应物更有希望的抗幽门螺杆菌。结论最有效的硝基呋喃衍生物在1,3,4-噻二唑环的C-2位(化合物6i)含3-甲氧基苄基哌嗪侧基(化合物6i),在所研究的浓度100-25?μg/盘下显示出较强的抗幽门螺杆菌潜能。 (IZD≥>20μm)对所有研究过的对幽门螺杆菌有抗甲硝唑作用的菌株。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号